Buprenorphine Dose Alteration Study - 1 - Tabular View

Tracking Information

First Received Date ^ICMJE

September 20, 1999

Last Updated Date

June 23, 2005

Start Date ^ICMJE

December 1991

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Opioid withdrawal
Subjective dose estimate
Drug effect characteristics: ARCI
Physiological changes in: pupil diameter
Physiological changes in: blood pressure
Physiological changes in: heart rate
Physiological changes in: respiration
Physiological changes in: skin temperature

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00000219 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Buprenorphine Dose Alteration Study - 1

Official Title ^ICMJE

Buprenorphine Dose Alteration Study

Brief Summary

The purpose of this study is to examine the effects in buprenorphine dose alterations in opioid dependent individuals being maintained on buprenorphine.

Detailed Description

Study Phase

Phase I

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment, Double-Blind

Condition ^ICMJE

Opioid-Related Disorders

Intervention ^ICMJE

Drug: Buprenorphine

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

July 2001

Primary Completion Date

Eligibility Criteria ^ICMJE

Please contact site for information.

Gender

Male

Ages

19 Years to 41 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00000219

Responsible Party

Study ID Numbers ^ICMJE

NIDA-06969-1, R01-06969-1

Study Sponsor ^ICMJE

National Institute on Drug Abuse (NIDA)

Collaborators ^ICMJE

University of Vermont

Investigators ^ICMJE

Principal Investigator:

Warren Bickel, Ph.D.

University of Vermont

Information Provided By

National Institute on Drug Abuse (NIDA)

Verification Date

April 1992

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP